Serum Institute of India officially halts the trial of Astrazeneca-Oxford vaccine in India

"We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials. We are following DCGI's instructions and will not be able to comment further on trials", said Adar Poonawala, CEO of Serum Institute of India in a statement. Poonawala added that the company is following the DCGI’s instructions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/32dvmdY
via IFTTT